期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮对2型糖尿病大鼠心肌病变治疗的研究 被引量：2

下载PDF
导出
摘要 目的　探讨 2型糖尿病大鼠心肌组织血管紧张素Ⅱ (AngⅡ )、醛固酮 (Ald)、转化生长因子 β1 (TGF β1 )的变化及胰岛素增敏剂罗格列酮对其影响。方法　采用放免法检测血浆及心肌AngⅡ、Ald;电镜下观察心肌超微结构 ;免疫组化方法检测心肌组织TGF β1 的变化 ;用Masson三色染色观察心肌胶原含量变化。结果　糖尿病大鼠血浆及心肌组织中AngⅡ、Ald的水平明显高于正常对照大鼠 ,罗格列酮治疗组与糖尿病大鼠相比无显著性差异 ;糖尿病大鼠心肌组织TGF β1含量增加 ,罗格列酮治疗组较糖尿病组减少 (P <0 .0 1 ) ;电镜观察罗格列酮治疗组大鼠心肌的病理变化明显减轻。结论　 2型糖尿病大鼠血浆和心肌组织AngⅡ、Ald升高 ,心肌TGF β1含量增加 ,罗格列酮治疗后可延缓糖尿病心肌病变的进展。
作者 王绵 崔炜 张力辉 苏胜偶 张玉华 乔丽敏
机构地区 河北医科大学第二医院内分泌科 河北医科大学第二医院心血管内科 河北医科大学第二医院核医学科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2004年第10期939-941,共3页 Chinese Journal of Gerontology
关键词 罗格列酮 糖尿病大鼠 心肌组织 TGF-Β1 2型糖尿病 治疗组 血浆 结论 水平 变化
分类号 R587.1 [医药卫生—内分泌] R542 [医药卫生—心血管疾病]
  • 相关文献

参考文献13

  • 1Martens FM,Visseren FL,Lemay Y,et al.Metabolic and additional vascular effects of thiazolidinediones[J]. Drug, 2002;62(10): 1463-80.
  • 2Sidhu JS, Kaski JC. PPAR:A potential therapeutic target in the management of ischemic heart disease[J]. Heart, 2001;86(3): 255-8.
  • 3Shimabukuro M,Higa S,Shinzato T ,et al.Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats[J]. Metabolism, 1996;45(9): 1168-73.
  • 4Shiomi T,Tsutsui H,Hayashidani S, et al.Piglitazone, a peroxisome proliferator-activated receptorγ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J]. Circulation, 2002;106: 3126-32.
  • 5Sidell RJ, Cole MA, Draper NJ, et al.Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker fatty rat heart [J]. Diabetes, 2002;51(4): 1110-7.
  • 6Takeda K, Ichiki T, Tokunou T, et al.Peroxisome proliferator-activated receptor gamma activators down-regulate angiotensin II type 1 receptor in vascular smooth muscle cells [J]. Circulation, 2000;102(15): 1834-9.
  • 7Marx N, Schonbeck U, Lazar MA, et al.Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth cells [J]. Circ Res, 1998;83(11): 1097-103.
  • 8Mehrabi MR,Thalhammer T,Haslmayer P,et al.The peroxisome proliferator-activated receptor gamma(PPARγ) is highly expressed in human heart ventricles[J]. Biomed Pharmacother, 2002;56: 407-10.
  • 9Yue TL,Chen J, Wao W, et al.In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone [J]. Circulation, 2001;104(21): 2588-94.
  • 10Yamamoto K,Ohki R,Lee RT, et al.Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocyte[J]. Circulation, 2001;104(14): 1670-75.

二级参考文献10

  • 1Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrine Reviews, 1985,6 : 45-86.
  • 2Bryer-Ash M, Foilett L, Hodges N, et al. Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor activity in the rat in vivo. Metabolism, 1995,44:705-711.
  • 3Proietto J, Filippis A, Nakhla C, et al. Nutrient-induced insulin resistance. Mol Cell Endocrinol, 1999,151:143-149.
  • 4Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia,1996,39:1569-1576.
  • 5Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats.J Am Soc Nephrol, 2000,11 : 669-683.
  • 6Dominguez JH, Tang N, Xu W, et al. Studies of renal injury Ⅲ: lipid-induced nephropathy in type Ⅱ diabetes. Kidney Int,2000,57 : 92-104.
  • 7Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Inter Mecl, 1998,158:998-1004.
  • 8Daniels MC, McClain DA, Crook ED. Transcriptional regulation of transforming growth factor beta by glucose: investigation into the role of the hexosamine biosynthesis pathway. Am J Med Sci, 2000,319:138-142.
  • 9Michel O, Heudes D, Lamarre I, et al. Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats. Kidney Int, 1997,52:1532-1542.
  • 10李颖健,刘志红,刘栋,朱加明,郭啸华,黎磊石.己糖胺通路的活化介导系膜细胞转化生长因子β1的表达[J].肾脏病与透析肾移植杂志,2000,9(4):303-310. 被引量：12

共引文献346

同被引文献14

  • 1Schuyler M, Niewoehner D, Inkley S, et al. Abnormal lung elasticity in ju- venile diabetes mellitus. Am Rev Resp Dis, 1976,113 : 37-41.
  • 2Guan YF, Breyer MD. Proliferator activation receptors (PPARs) : novel therapeutic targets in renal disease. Kidney Int,2001,60:14-30.
  • 3Robert AB, Flanders KC, Heine UI, et al. Transforming Growth factor- : multifunctional regulator of differentiation and development. Philos Trans R Soc Lond B Biol Sci, 1990,327 : 145-154.
  • 4Robert AB, Mcune BK, Sporn MB. TGF-beta : Regulation of extracellular matrix. Kidney Int, 1992,41:557-559.
  • 5Wen FQ, Kohyama T, Skold CM, et al. Glucocorticoids modulate TGF-be- ta production by human fetal lung fibroblasts. Inflammation ,2003,27:9- 19.
  • 6Warburton D, Beliusei S. The molecular genetics of lung morphogenesis and injury repair. Paediatr Respir Rev ,200d ,5:283-287.
  • 7Alker TR, Moore SM, Lawson MF, et al. Platelet-derived growth factor- BB and thrombin active phosphoinositide 3-kinase and protein kinase B : role in mediating airway smooth muscle proliferation. Mol Pharmacol, 1998,54 : 1007-1015.
  • 8Awliczak R, Han C, Huang XL, et al. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator activated receptor ~ activation in human lung epithelial cells. J Biol Chem, 2002,277 : 33153-33163.
  • 9Urgess HA, Daugherty LE, Thatcher TH, et al. PPAR-gamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production : implications for therapy of lung fibrosis. Am J Phys- iol Lung Cell Mol Physio1,2005 ,288 :1146-1153.
  • 10Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomer- ulosclerosis in rats. Kidney Int,2001,59 : 1899-1910.

引证文献2

二级引证文献9

中国老年学杂志
2004年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部